REG - AstraZeneca PLC - AZ agreement with Grünenthal for rights to Zomig <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

07/06/2017 07:16

RNS Number : 3790H
AstraZeneca PLC
07 June 2017
7 June 2017
ASTRAZENECA ENTERS AGREEMENT WITH GRNENTHAL TO DIVEST RIGHTS TO MIGRAINE TREATMENT ZOMIG
AstraZeneca today announced that it has entered an agreement with Grnenthal for the global rights to Zomig(zolmitriptan)outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca's strategic focus.
Grnenthal will pay AstraZeneca $200 million upon completion. AstraZeneca will also receive up to an additional $102 million in future milestone payments. Grnenthal will acquire the rights to Zomig in all markets outside Japan, including the US, where the rights were previously licensed to Impax Pharmaceuticals (Impax). Impax will continue to market Zomig in the US. AstraZeneca will continue to manufacture and supply the medicine to Grnenthal during a transition period.
Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca said: "Grnenthal is an established partner with expertise in the treatment of pain. It is well placed to ensure patients continue to benefit from Zomig, and to extend the commercial potential of the medicine through its dedicated salesforce."
Gabriel Baertschi, CEO of Grnenthal said: "Migraine is a very debilitating disease with more than 75 million people worldwide suffering from attacks that can lead to sensitivity to light or sound, to nausea or even vomiting. The acquisition of the well-established Zomig products complements our existing pain portfolio. Migraine has been one of the very few main pain indications we haven't yet been able to offer a solution for. This is an important step to reach our ambition to become a 2 billion company by 2022. It will also support our efforts to bring four to five innovative products to market in the same timeframe."
Financial considerations
In 2016, revenues from Zomig outside Japan were $96 million, including Product Sales and Externalisation Revenue. The transaction is expected to complete in the second quarter of 2017, subject to customary closing conditions and regulatory clearances. The net consideration from the agreement will be reported as Other Operating Income in the Company's financial statements.The agreement does not impact the Company's financial guidance for 2017.
About Zomig
Zomig (zolmitriptan) is indicated for the acute treatment of migraine, and for the acute treatment of cluster headache in the EU. Zomig is available in three formulations: An oral tablet, orally dispersible tablet and nasal spray.
About Grnenthal
The Grnenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a 2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grnenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grnenthal Group worldwide. In 2016, Grnenthal achieved revenues of approx. 1.4 bn. More information: www.grunenthal.com. Follow us on LinkedIn: @GrunenthalGroup
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCSSLSMWFWSESM